Gilead Announces Executive Promotions
July 27 2015 - 4:30PM
Business Wire
Gilead Sciences, Inc. (Nasdaq:GILD) today announced the
promotion of William Lee, PhD to Executive Vice President,
Research, and Brett Pletcher to Executive Vice President and
General Counsel. Dr. Lee and Mr. Pletcher will both join Gilead’s
senior leadership committee.
Dr. Lee joined Gilead in 1991 and was promoted to Senior Vice
President, Research in 2000. He has led the expansion of the
company’s research activities across a range of therapeutic areas,
including HIV, liver diseases, hematology/oncology, inflammation
and respiratory diseases and cardiovascular conditions. He reports
to Norbert Bischofberger, PhD, Executive Vice President, Research
and Development and Chief Scientific Officer. Prior to joining
Gilead, Dr. Lee worked at California Biotechnology, Inc. and
Syntex. He received his BS in Chemistry from the University of
Massachusetts, PhD in Chemistry from the University of California
at San Diego and did postdoctoral work at the Ecole Polytech
Federal Lausanne and the University of California at Santa
Barbara.
“Over the past nearly 25 years, Bill has helped Gilead bring
multiple product candidates from early stage research into
development. His contributions to the discovery and advancement of
internal drug candidates and evaluation of external candidates for
potential partnership have allowed Gilead to bring important new
medicines to patients around the world,” commented Dr.
Bischofberger.
Mr. Pletcher joined Gilead in 2005 and most recently served as
Senior Vice President and General Counsel. With this promotion, Mr.
Pletcher also becomes corporate Secretary for the company. He
reports to Gregg Alton, Executive Vice President, Corporate and
Medical Affairs. Prior to joining Gilead, Mr. Pletcher was a
partner in the law firm of Gunderson Dettmer, LLP, where he focused
on providing corporate and securities services to emerging growth
public and private companies and venture capital investors. He
received his bachelor’s degree in economics and political science
from the University of California, Riverside and his law degree
from the University of California, Berkeley’s Boalt Hall School of
Law. He is a member of the California State Bar and the Nasdaq
Listing and Hearing Review Council.
“Brett’s leadership has been instrumental in helping Gilead
manage a period of significant growth and complexity, particularly
as we introduce medicines in new geographies. His expertise has
helped Gilead protect its intellectual property around the world
and ensure compliance across countries with vastly different legal
systems,” commented Mr. Alton.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company’s mission is to advance the care of
patients suffering from life-threatening diseases. Gilead has
operations in more than 30 countries worldwide, with headquarters
in Foster City, California.
For more information on Gilead Sciences, please
visit the company’s website at www.Gilead.com, follow Gilead on
Twitter (@GileadSciences) or call Gilead Public Affairs at
1-800-GILEAD-5 or 1-650-574-3000.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150727006228/en/
Gilead Sciences, Inc.Investors:Patrick O’Brien,
650-522-1936MediaAmy Flood, 650-522-5643
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024